UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 7, 2003
PROTEIN DESIGN LABS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-19756 | 94-3023969 |
| (State of other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
34801 Campus Drive
Fremont, California 94555
(Address of principal executive offices including zip code)
(510) 574-1400
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Matters.
On July 7, 2003, Protein Design Labs, Inc. ("PDL") announced the offering of up to $200 million of convertible subordinated notes due 2023 in a private placement.
The foregoing matter is discussed in greater detail in PDL's press release, a copy of which is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
Exhibit No. | Description |
| | |
99.1 | Press Release dated July 7, 2003 regarding convertible subordinated notes due 2023. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 7, 2003 | PROTEIN DESIGN LABS, INC. By: /s/ Sergio Garcia-Rodriguez
Sergio Garcia-Rodriguez
Vice President, Legal, General Counsel and
Assistant Secretary |
| | |
INDEX TO EXHIBITS
* Also provided inPDF format as a courtesy.
